“as we accelerate the program, as you've seen, started phase three programs already for colorectal cancer, and earlier this year, we'll also start with first-line phase three with non-small cell lung cancer and then endometrial cancer and bladder cancer, including combinations with our ADC portfolio.”

In context

“t. PD-L1B and another phase three program ongoing in non-small cell lung cancer. And a number of phase one ADCs that's differentiated, including using the integrin beta-six antigen as a marker with new payloads including topo two and different new orastatin-based pilots. So integration overall, Seagen going very, very well. Regarding 4404, it is a differentiated molecule. What we've seen in the preclinical data was a hundredfold increase for the affinity. For PD-1 in the presence of VGFA and binding to all isoforms of VGFA. So preclinical data highly encouraging. Overall, encouraged by the field now. As you know, we've recently seen from China first-line non-small cell lung data that was positive. The data we've seen with a combination of 4404 with chemotherapy are highly encouraging, and as we accelerate the program, as you've seen, started phase three programs already for colorectal cancer, and earlier this year, we'll also start with first-line phase three with non-small cell lung cancer and then endometrial cancer and bladder cancer, including combinations with our ADC portfolio. Albert Bourla: Thank you, Chris. Very exciting. So thank you very much, everyone. Clearly, I'm very proud of what we achieved in 2025 in multiple horizons. The last piece of the puzzle was revealed today with the fourth quarter results, which were stellar. We beat with a significant margin revenues and earnings in the face of the lowest ever COVID season, but generated the lowest ever revenues because of the way that this strain was mild. Now we are already in 2026. And this is a pivotal year because it marks the first year of an LOE cycle but already started. This year. And we've been preparing for that for many years with the acquisitions we have done, strategic and licensing agreements, while also we were sharpening our focus on the most impactful internal programs. Our US and internat”